Meanwhile, in Zhang's study, 30mg/kg of sorafenib was administrated in vivo studies; Finally, since sorafenib is a multi-target antitumor drug with multiple signaling pathways involved, the mechanism of promoting invasion and metastasis found in our study mainly relied on IL-6/HIF-1α/PFKFB3 signaling pathway, and Zhang et al found Sorafenib promotes invasiveness and the metastatic potential of HCC by down-regulating expression of HTATIP2 via JAK-STAT3 signaling. This evidence concerns the gene IL6 and hepatocellular carcinoma.